Heart failure and COPD: Partners in crime?

Hannink, Jorien; Helvoort, H.A.C. van; Dekhuijzen, P.N.R.; Heijdra, Yvonne F.

doi:10.1111/j.1440-1843.2010.01776.x

Cited by 25 publications

(26 citation statements)

References 71 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Like cardiovascular diseases, there is evidence that suggests that stable COPD is associated with low grade systemic inflammation 12. The risk of underlying ischemic heart disease is greater in patients with moderate or severe airflow obstruction and high circulating C-reactive protein (CRP), suggesting a certain influence of this inflammatory marker on cardiac risk.…”

Section: Pathophysiologymentioning

confidence: 99%

“…BNP levels ranging from 100 pg/mL to 500 pg/mL in COPD patients may be due to cor pulmonale (right ventricular stretch), moderate left ventricular failure, or both. Finally, although not specifically tested in patients with a history of COPD, BNP > 500 pg/mL is suggested by several authors to indicate acute HF in COPD patients 1,10,12,33. Recently, Macchia et al demonstrated that a BNP cutoff point of 160 pg/mL in COPD patients increases, more than 10 times, the probability of finding a ventricular dysfunction with echocardiography 8.…”

Section: Diagnosismentioning

confidence: 99%

“…Recently, Macchia et al demonstrated that a BNP cutoff point of 160 pg/mL in COPD patients increases, more than 10 times, the probability of finding a ventricular dysfunction with echocardiography 8. For NT-proBNP, a value < 300 pg/mL excludes HF, and a value > 450 pg/mL (for patients < 50 years) or a value > 900 pg/mL (for those ≥50 years) identifies HF in patients with previous COPD presenting with acute dyspnea 12. For excluding HF, the sensitivity was 94%, while for detecting H F, the specificity was 84%.…”

Section: Diagnosismentioning

confidence: 99%

See 2 more Smart Citations

The association between COPD and heart failure risk: a review

Miguel-Díez¹,

Morgan²,

García³

2013

COPD

161

102

View full text Add to dashboard Cite

Chronic obstructive pulmonary disease (COPD) is commonly associated with heart failure (HF) in clinical practice since they share the same pathogenic mechanism. Both conditions incur significant morbidity and mortality. Therefore, the prognosis of COPD and HF combined is poorer than for either disease alone. Nevertheless, usually only one of them is diagnosed. An active search for each condition using clinical examination and additional tests including plasma natriuretic peptides, lung function testing, and echocardiography should be obtained. The combination of COPD and HF presents many therapeutic challenges. The beneficial effects of selective β1-blockers should not be denied in stable patients who have HF and coexisting COPD. Additionally, statins, angiotensin-converting enzyme inhibitors, and angiotensin-receptor blockers may reduce the morbidity and mortality of COPD patients. Moreover, caution is advised with use of inhaled β2-agonists for the treatment of COPD in patients with HF. Finally, noninvasive ventilation, added to conventional therapy, improves the outcome of patients with acute respiratory failure due to hypercapnic exacerbation of COPD or HF in situations of acute pulmonary edema. The establishment of a combined and integrated approach to managing these comorbidities would seem an appropriate strategy. Additional studies providing new data on the pathogenesis and management of patients with COPD and HF are needed, with the purpose of trying to improve quality of life as well as survival of these patients.

show abstract

Section: Pathophysiologymentioning

confidence: 99%

Section: Diagnosismentioning

confidence: 99%

Section: Diagnosismentioning

confidence: 99%

See 1 more Smart Citation

The association between COPD and heart failure risk: a review

Miguel-Díez¹,

Morgan²,

García³

2013

COPD

161

102

View full text Add to dashboard Cite

show abstract

“…Számos adat utal arra, hogy a COPD és a szívelég-telenség együttes előfordulása gyakoribb, mint ahogy prevalenciájuk alapján az várható lenne (2). A szíve-légtelenség gyakoriságáról és típusáról (szisztolés vagy diasztolés, bal vagy jobb szívfelet érintő) ellentmondásosak az adatok, ám ismert, hogy a jobbkamra-funkció károsodása rontja a COPD-s betegek prognózisát (3).…”

Section: Bevezetésunclassified

A jobbkamra-funkció echokardiográfiás és szív MR-paramétereinek összehasonlítása COPD-ben

Hajdu¹,

Vértes²,

Meiszterics³

et al. 2017

Cardiologia Hungarica

View full text Add to dashboard Cite

Bevezetés: A COPD-s betegek prognózisát rontja a jobbkamra-diszfunkció (JK). Rutinszerűen echokardiográfi át használunk a JK-méret és -funkció megítélésére, ám ennek klinikai értéke COPD-ben nem tisztázott. A szív MR számít referenciamód-szernek, de nincs konszenzus arról, hogy a jobb kamrai volumenhez számítandó-e a trabekulák és a papilláris izmok tér-fogata. Így kutatásunk célja a JK-t jellemző echokardiográfi ás és szív MR-paraméterek közti összefüggések vizsgálata volt COPD-s betegekben. A trabekulák és papilláris izmok beszámításának hatását is tanulmányoztuk a JK-i méret és funkció szív MR-rel mért paramétereire. Betegek és módszerek: 22 fő, GOLD II. és III. stádiumú COPD-s beteget (62±9 év) vizsgáltunk. Echokardiográfi ával határoztuk meg a JK-i végszisztolés (ES) és végdiasztolés (ED) areát és a falvastagságot. A JK-funkciót TAPSE és RVFAC mérésével, valamint a tricuspidalis anuluszon mért szisztolés (S) sebességgel jellemeztük. Szív MR-rel JK-térfogat (MR-tér-fogat), ejekciós frakció (MR-EF) és izomtömeg-index (MR-tömeg-index) meghatározás történt. A manuális kontúrozás során a trabekulák és a papilláris izmok a kamrai volumen részét képezték, majd egy pixelintenzitáson alapuló programmal hozzászámítottuk a kamrai izomtömeghez. Eredmények: A JK-i átmérő és area értékek szignifi kánsan korreláltak az MR-térfogattal, a falvastagság pedig az MR-tömeg-indexszel. Az MR-EF szignifi kánsan korrelált a JK hosszanti átmérőjére normalizált TAPSE és tricuspidalis S-értékekkel, míg az RVFAC-cal nem. A trabekulák és papilláris izmok beszámítása szignifi kánsan csökkentette az MR-térfogatot (ED: -26,5±9,6; ES: -17,3±6,9 ml). Az MR-EF (+3,6±2,6%) és az MR-tömeg-index (ED:+27,8±10,0; ES:+18,1±7,2 g/m 2 ) szignifi kánsan nőtt. Következtetések: Az echokardiográfi a rutinszerűen alkalmazható a JK méretének és funkciójának meghatározására COPD-s betegeknél. A TAPSE és a tricuspidalis S a preferálandó módszerek a JK-funkció megítélésére. A trabekulák és papilláris izmok beszámítása a szív MR-mérések során szignifi kánsan befolyásolja az MR-rel nyert térfogat, tömeg és EF-értékeket.Correlations between echocardiographic and CMR-derived parameters of right ventricular function in COPD Background: In COPD right ventricular (RV) failure is linked to worse outcome. Though echocardiography is the common method for the assessment of RV size and function, its clinical value in COPD is not well defi ned. CMR is the reference technique, but it is not known, if trabeculae and papillary muscles should be included or excluded from the muscles during analysis. Thus we aimed to investigate the correlations between echocardiographic and CMR-derived parameters of the RV size and function in COPD patients. In addition, our aim was to determine the impact of including trabeculae and papillary muscles on RV volumes and function as assessed by CMR. Patients and methods: 22 COPD patients (62±9 years) in stages GOLD II. and III. were involved. RV end-systolic (ES) and end-diastolic (ED) area and RV wall thickness were measured by echocardiograph...

show abstract

“…On the other hand, there is a large elderly population with various cardiovascular complications due to aging populations. Except for the CVDs, there are more and more age-associated chronic comorbid conditions with adverse cardiac consequences, which include type 2 diabetes mellitus, chronic obstructive pulmonary diseases, and chronic renal disease (Al-Ahmad et al, 2001;Kamalesh, 2007;Hannink et al, 2010). Therefore, it is reasonable to focus on the prevention and treatment of disorders responsible for HF.…”

Section: Epidemiology and Pathophysiology Of Hfmentioning

confidence: 99%

Roles of SIRT3 in heart failure: from bench to bedside

Liu

Song

et al. 2016

J. Zhejiang Univ. Sci. B

View full text Add to dashboard Cite

Heart failure (HF) represents the most common endpoint of most cardiovascular diseases (CVDs) which are the leading causes of death around the world. Despite the advances in treating CVDs, the prevalence of HF continues to increase. It is believed that better results of prognosis are obtained from prevention rather than additional treatment for HF. Therefore, it is reasonable to prevent the development of CVDs or other complications to HF. Most types of HF are attributed to contractile dysfunction, cardiac hypertrophy or remodeling, and ischemic injuries. SIRT3 is a mitochondrial nicotinamide adenine dinucleotide (NAD + )-dependent deacetylase whose substrates vary from metabolic biogenesis-associated proteins to stress-responsive proteins. In recent years, a number of studies have highlighted the cardio-protective role of SIRT3 and, as such, efforts have been made to induce over-expression or increased activity of this protein. In this review, we provide an overview of the roles of SIRT3 in cardiac hypertrophy induced by pressure overload or agonists and cardiomyocytes ischemic injuries. Moreover, we will introduce the application of SIRT3 agonists in the prevention of cardiac hypertrophy and ischemia reperfusion injury.

show abstract

Heart failure and COPD: Partners in crime?

Cited by 25 publications

References 71 publications

The association between COPD and heart failure risk: a review

The association between COPD and heart failure risk: a review

A jobbkamra-funkció echokardiográfiás és szív MR-paramétereinek összehasonlítása COPD-ben

Roles of SIRT3 in heart failure: from bench to bedside

Contact Info

Product

Resources

About